Human monoclonal antibody therapies, which embrace over 570 agents in the clinical field, have become one of the fastest-growing cancer treatments. Now, a novel therapy based on bispecific antibodies may be a further refinement in oncology treatment that overcomes the limitations of current monoclonal antibody therapies.
What are Bispecific Antibodies?
Bispecific antibodies (BsAbs) are engineered proteins that can simultaneously recognize and bind two separate and unique targets (antigens or different epitopes of the same antigen). Given the fact of dual functionalities, BsAbs are different from normal monoclonal antibodies.
Therapeutics and drugs based on bispecific antibodies are expected to be the next big advance in oncology, hematology in particular. Different from cytotoxic chemotherapy or targeted agents, the distinct mechanism of action of bispecific antibody drugs may enable patients to fight against cancers with the immune system.
The Development of Bispecific Antibodies Therapeutics
Experts agreed that bispecific antibodies have the potential to impact the treatment of lymphoma and other hematologic malignancies, and thus hundreds of next-generation bispecific antibodies are in clinical trials and at least 2 therapeutics have been approved in the United States.
A report released by Kuick Research indicates that the global market for bispecific antibody therapeutics is predicted to reach over $10 billion by 2026.
Creative Biolabs has been dedicated to the development of bispecific antibodies for years and is always at the forefront place. A comprehensive list of bispecific antibody products and services are available harnessing its cutting-edge platforms and methods. Up to now, this company can perform BsAb designing, engineering, analyzing, purifying, and manufacturing with trustworthy quality.
Bispecific Antibodies Design
As previously pointed out, BsAbs are artificially designed molecules, which enhance the difficulties in development at the early stage. Fortunately, now service providers can design customized bispecific antibodies according to research target and clinical practice. For instance, Creative Biolabs helps researchers design bispecific antibodies targeting different epitopes, ligands, receptors, and immune cells.
Over 60 BsAbs now have been designed and widely applied to cancer, inflammatory, autoimmune, and other diseases. Other bispecific antibody designs may be based on different modes of action and therapeutic applications, including oncology, hematology, immunology, ophthalmology, and radio-immunotherapy.
Bispecific Antibodies Engineering
Chemical conjugation, hybrid hybridomas, and genetic engineering have made it possible to adjust the properties of BsAbs such as valency, size, half-life, and flexibility when specific requirements occur. Bispecific IgGs are one of the results of BsAbs engineering, keeping the general size and structure of a normal IgG as well as serum high stability, half-life, and tissue penetration.
Other services of bispecific antibody development in the market include bispecific antibody purification to improve efficacy, bispecific antibody analysis for qualified preclinical results, and bispecific antibody manufacturing to satisfy the great need of therapeutic proteins.
Clinical Trial Results of Bispecific Antibody Development
New data of several agents were presented at the 2020 American Society of Hematology (ASH) annual meeting. Mosunetuzumab and glofitamab, which are T-cell-engaging bispecific antibodies designed to bind to the cancer cell and the T cell simultaneously, show promising effects on patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL).
Some experts also believe that mosunetuzumab may be hopeful for patients who cannot tolerate immunochemotherapy and is specifically potential in earlier treatment settings.
Though bispecific antibodies are prone to advance oncology treatment because of those encouraging therapeutic studies, the side effects such as toxicity, cytokine release syndrome (CRS), and lack of significant tumor response also deserve more attention in bispecific antibody research. Modification of binding specificity and engineering bispecific antibodies may help the proteins exert better influence in oncology.
Comments
Post a Comment